AN EXPERIENCE OF TRIMETAZIDINE USAGE IN COMORBIDITY
https://doi.org/10.15829/1560-4071-2018-3-37-42
Abstract
Aim. To assess the dynamics of heart rate variability (HRV) during the therapy with trimetazidine instable angina patients comorbid with diabetes.
Material and methods. Totally, 110 stable angina patients studied, of III functional class (FC), comorbid with type 2 diabetes (DM2), that is 53 with diabetic vegetative cardial neuropathy, and other 57 with no diabetes, that is with no vegetative cardial neuropathy, investigated with hardware and software complex.
Results. Usage of trimetazidine instable angina patients of III FC, comorbid with DM2, makes it to improve the myocardial index to normal levels, to restore variability parameters, clinical condition of the patient, and facilitates the improvement of diabetic neuropathy.
Conclusion. Usage of trimetazidine is practically worthy, making it to improve prognosis in coronary heart disease comorbid with DM2.
About the Authors
I. V. Kochetkova
N. N. Burdenko Voronezh State Medical University.
Russian Federation
Voronezh.
Russian Federation
Voronezh.
T. M. Chernykh
N. N. Burdenko Voronezh State Medical University.
Russian Federation
Voronezh.
Russian Federation
Voronezh.
G. M. Panyushkina
N. N. Burdenko Voronezh State Medical University.
Russian Federation
Voronezh.
Russian Federation
Voronezh.
References
1. Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: Results from an international multicentre retrospective cohort study. Int J Cardiol 2013; 163 (3): 320-5.
2. Glezer MG, Saygitov RT. Adherence of Patients With Stable Angina to Treatment With Trimetazidine MR and Frequency of Emergency Medical Care: Results of the EFFECT Study. Kardiologija 2012; 11: 4-11. (In Russ.) Глезер М. Г., Сайгитов Р. Т. Приверженность больных со стабильной стенокардией к терапии Предукталом МВ и ее связь с частотой обращений за медицинской помощью по экстренным показаниям: результаты исследования ЭФФЕКТ. Кардиология 2012; 11: 4-11.
3. Peng S, Zhao M, Wan J, et al. The efficacy of trimetazidine on stable angina pectoris: A meta-analysis of randomized clinical trials. Int J Cardiol 2014; 177 (3): 780-5. DOI: 10.1016/j. ijcard.2014.10.149.
4. Glezer MG, Astashkin EI, Novikova MV. The mechanism of action of trimetazidine metabolic cytoprotector in acute ischemia/ reperfusion injury. Cardiosomatika 2014; 2: 24-30. (In Russ.) Глезер М. Г., Асташкин Е. И., Новикова М. В. Механизм действия метаболического цитопротектора триметазидина при остром ишемически-реперфузионном повреждении. Cardioсоматика 2014; 2: 24-30.
5. Grajek S, Michalak M. The effect of trimetazidine added to pharmacological treatment on all-cause mortality in patients with systolic heart failure. Cardiology 2015; 131 (1): 22-9. DOI: 10.1159/000375288. Epub 2015 Mar 27.
6. National guidelines RHFA, the RCS and RSMOT for the diagnosis and treatment of chronic heart failure (fourth revision). Journal of Heart Failure 2013; 14 (7): 379-472. (In Russ.) Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр) Сердечная недостаточность 2013; 14 (7): 379-472.
7. Sadkova EV, Streletskaya GN, Kochetkova IV. The study of heart rate variability in the evaluation of the functional state of the cardiovascular system in patients with diabetes. Youth innovation Bulletin. 2015; 4, 1: 74-5. (In Russ.) Садкова Е. В., Стрелецкая Г. Н., Кочеткова И. В. Исследование вариабельности сердечного ритма в оценке функционального состояния сердечно-сосудистой системы у больных сахарным диабетом. Молодежный инновационный вестник. 2015; 4, 1: 74-5.
8. Kochetkova IV, Kuchkovskaya TP, Chernykh TM. Use of cytoprotectors for the correction of disorders of the autonomic nervous system in patients with diabetes/In collection: Problems of modern medicine: current issues Collection of scientific papers on the results of international scientific-practical conference. 2015. p. 218-20. (In Russ.) Кочеткова И. В., Кучковская Т. П., Черных Т. М. Использование цитопротекторов для коррекции нарушений вегетативной нервной системы у больных сахарным диабетом/В сборнике: Проблемы современной медицины: актуальные вопросы Сборник научных трудов по итогам международной научно-практической конференции. 2015. c. 218-20.
9. Minakov EV, Kochetkova IV, Streletskaya GN. Prediction of the total effect of vegetative regulation of blood circulation in the treatment process. Doctor-graduate student. 2014; 63, 2.1: 191-6. (In Russ.) Минаков Э. В., Кочеткова И. В., Стрелецкая Г. Н. Прогнозирование суммарного эффекта вегетативной регуляции кровообращения в процессе лечения. Врач-аспирант. 2014; 63, 2.1: 191-6.
Review
For citations:
Kochetkova I.V., Chernykh T.M., Panyushkina G.M. AN EXPERIENCE OF TRIMETAZIDINE USAGE IN COMORBIDITY. Russian Journal of Cardiology. 2018;(3):37-42. (In Russ.) https://doi.org/10.15829/1560-4071-2018-3-37-42
Views:
986
Email this article 